Categories: JobsPharma Jobs

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).

Zanubrutinib will be marketed in India under the brand name BRUKINSA, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).

Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA.2 This extensive clinical program underscores BRUKINSA’s proven efficacy, strong safety profile, and broad therapeutic value.

“We look forward to bringing BRUKINSA to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines),” said Mr.Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd. “This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India with access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark’s ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies.”

Adam Roach, Senior Vice President and Head of Japan and Asia Pacific region for BeiGene (to be renamed BeOne Medicines) commented, “The introduction of BRUKINSA in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region. We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally.”

SWARNALATHA B

Recent Posts

Saga Lifesciences Ltd Walk-in On 21st November 2026 for QA,QC,Production,packing,Warehouse,R&D,F&D,ADL,TT

You have shared two job recruitment flyers from Saga Lifesciences Limited for upcoming walk-in interviews…

1 day ago

Acme Generics Pvt Ltd Walk-in OnSaturday, November 21, 2026 for Multiple Positions

This flyer announces a walk-in recruitment drive hosted by Acme Generics Pvt Ltd (a USFDA-approved…

1 day ago

O2h Discovery Walk-in  21st November 2026, Saturday Freshers & experience

𝗪𝗮𝗹𝗸-𝗶𝗻 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 – 𝗔𝗵𝗺𝗲𝗱𝗮𝗯𝗮𝗱 o2h Discovery is conducting a walk-in interview for multiple positions across…

1 day ago